Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Novogen Limited (KZIA : NSDQ)

• Company Description    Kazia Therapeutics Limited is an oncology-focused biotechnology company. It develops anti-cancer drugs as well as provides pharmaceutical research and development technology solutions. The company's lead program is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being developed to treat glioblastoma multiforme, the primary and most aggressive form of brain cancer. Kazia Therapeutics Limited, formerly known as Novogen Limited, is based in Sydney, Australia. Number of Employees: 12

• Price / Volume Information    Yesterday's Closing Price: $6.58 Daily Weekly Monthly 20 Day Moving Average: 2,620,387 shares Shares Outstanding: 1.01 (millions) Market Capitalization: $6.63 (millions) Beta: 2.64 52 Week High: $79.00 52 Week Low: $2.86 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 22.88% 17.81% 12 Week 89.49% 66.04% Year To Date -25.65% -29.78%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL Three International Towers Level 24 300 Barangaroo Avenue - Sydney,C3 2000 AUS ph: 61-2-9472-4101 fax: 61-2-9476-0388 investment.consultant@novogen.com http://www.kaziatherapeutics.com

• General Corporate Information    Officers John Friend - Managing Director and Chief Executive Officer Bryce Carmine - Chairman; Non-Executive Director Karen Krumeich - Chief Financial Officer Steven Coffey - Non-Executive Director Ebru Davidson - Non-Executive Director Peer Information Novogen Limited (CORR.) Novogen Limited (RSPI) Novogen Limited (CGXP) Novogen Limited (BGEN) Novogen Limited (GTBP) Novogen Limited (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 48669G303 SIC: 2834 Fiscal Year Fiscal Year End: June Last Reported Quarter: - Next Expected EPS Date: 11/21/25 Share - Related Items Shares Outstanding: 1.01 Most Recent Split Date: 4.00 (0.20:1) Beta: 2.64 Market Capitalization: $6.63 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/21/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - - 03/31/25 - - 12/31/24 - - Current Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - 0.21 Quick Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - - Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - - 12/31/24 - -2.46 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - -

Powered by Zacks Investment Research ©